Mikael Dolsten

Board of Governors

President, Worldwide Research and Development
Senior Vice President, Pfizer Inc

Mikael Dolsten, MD, PhD is President of Worldwide Research and Development (WRD), and Executive Vice President, of Pfizer Inc. He is focused on advancing the company's pipeline and scientific leadership in small molecule medicines, biotherapeutics and vaccines.

WRD contains Pfizer's research units, including Cardiovascular & Metabolic Disease, Neuroscience, Pain, Oncology, Inflammation & Remodelling, Immunoscience, Vaccines and Rare Disease, as well as the Centers for Therapeutic Innovation (CTI) and the biotech unit Rinat. Dr. Dolsten leads Pfizer's groups in safety, regulatory and development operations, and external R&D innovation in addition to science-based teams in biosimilars R&D, pharmaceutical sciences, drug safety R&D and large and small molecule discovery and development.

Prior to joining Pfizer in 2009, Dr. Dolsten was President of Wyeth Research. Before joining Wyeth, he served as Executive Vice President at Boehringer Ingelheim. His earlier career as a research leader included positions with AstraZeneca, Pharmacia and Upjohn.

Dr. Dolsten earned his PhD in tumor immunology and MD from the University of Lund in Sweden.

Dr. Dolsten is a fellow of the New York Academy of Medicine, a governor of the New York Academy of Sciences, and a member of the Board of Trustees of the New York Hall of Science. A member of the Biomedical Advisory Council of The Pharmaceutical Research and Manufacturers of America (PhRMA), Dr. Dolsten also serves on the PhRMA Foundation Board of Directors, and is a member of the Government University Industry Research Roundtable (GUIRR). Dr. Dolsten has published approximately 150 articles in international journals.